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OBJECTIVE — Bedtime administration of 5.0 mg of the 2-adrenergic agonist terbutaline
prevents nocturnal hypoglycemia but causes morning hyperglycemia in type 1 diabetes. We
tested the hypothesis that 2.5 mg terbutaline prevents nocturnal hypoglycemia without causing
morning hyperglycemia.
RESEARCH DESIGN AND METHODS — This was a randomized double-blind cross-
over pilot study (placebo, 2.5 mg terbutaline, and 5.0 mg terbutaline) in 15 patients with type 1
diabetes.
RESULTS — Mean  SE nadir nocturnal plasma glucose concentrations were 87  14 mg/dl
followingplacebo,10014mg/dlfollowing2.5mgterbutaline,and12213mg/dlfollowing
5.0 mg terbutaline (P  0.05 vs. placebo). Nadir levels were 50 mg/dl in 5, 2, and 0 patients
(P  0.05 vs. placebo), respectively. Morning levels were 113  18, 127  17, and 183  19
mg/dl (P  0.02 vs. placebo), respectively.
CONCLUSIONS — Terbutaline may be shown to be effective and safe in the prevention of
nocturnal hypoglycemia in type 1 diabetes in a suitably powered randomized controlled trial.
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I
atrogenic hypoglycemia is the limiting
factor in the glycemic management of
diabetes(1).Mostepisodesofhypogly-
cemia occur at night, speciﬁcally during
sleep, in type 1 diabetes—a ﬁnding in the
DiabetesControlandComplicationsTrial
(2) that continues to be documented
(3,4). Sympathoadrenal responses to hy-
poglycemia are reduced further during
sleep(5,6),and,probablybecauseoftheir
markedly reduced sympathoadrenal re-
sponses, patients with type 1 diabetes are
substantiallylesslikelytobeawakenedby
hypoglycemia than nondiabetic individu-
als (6,7).
Amongtheapproachestothepreven-
tion of nocturnal hypoglycemia in type 1
diabetes, we found bedtime administra-
tion of a conventional snack, uncooked
cornstarch, or an -glucosidase inhibitor
to be ineffective (3). In contrast, bedtime
administration of the epinephrine-
simulating 2-adrenergic agonist ter-
butaline in a dose of 5.0 mg prevented
nocturnal hypoglycemia (3). However, it
also caused hyperglycemia the following
morning. Therefore, we used a random-
ized double-blind crossover design (pla-
cebo, 2.5 mg terbutaline, and 5.0 mg
terbutaline) in a pilot study to test the hy-
pothesis that bedtime administration of
2.5mgterbutalinepreventsnocturnalhy-
poglycemia without causing morning hy-
poglycemia in patients with aggressively
treated type 1 diabetes.
RESEARCH DESIGN AND
METHODS— Fifteen patients (seven
women) with type 1 diabetes gave their
written consent to participate in this
study, which was approved by the Wash-
ington University Human Research Pro-
tection Ofﬁce and conducted at the
institution’s General Clinical Research
Center. Mean  SD age was 28.6  7.5
years, BMI 29.3  5.6 kg/m
2, duration of
type1diabetes14.97.0years,andA1C
7.1  0.5%. Subjects were selected for an
A1C 8.0% and the absence of diabetes
complications or use of a potentially in-
terfering medication. Nine subjects were
using continuous subcutaneous insulin
infusion with insulin analogs, and six
were using multiple daily injection with
insulin analogs (aside from one using
basal NPH insulin and one using prandial
regular insulin).
As in our earlier study (3), the pa-
tients pursued their usual activities and
used their individual treatment regimens
with guidance from their individual care-
givers throughout the study. They were
admitted to the Washington University
General Clinical Research Center early in
the evening on three occasions. Venous
blood samples for plasma glucose mea-
surements (YSI Glucose Analyzer; Yellow
Springs Instruments, Yellow Springs,
OH)weredrawnat15-minintervalsfrom
2200 h through 0700 h. Glucose levels
40 mg/dl were treated with small doses
of intravenous glucose (3).
One of three oral bedtime treat-
ments was administered, in random se-
quence and in double-blind fashion, at
2200h.Theseincludedplacebo,2.5mg
terbutaline (Brethine; Novartis Pharma-
ceuticals, East Hanover, NJ), and 5.0
mg terbutaline.
Statistical methods
Data are expressed as means  SE except
where SD is speciﬁed. Time- and condi-
tion-relateddatawereanalyzedbymixed-
model repeated-measures ANOVA.
Contrasts of interest were assessed with
a t test. P values  0.05 were consid-
ered to indicate statistically signiﬁcant
differences.
RESULTS— Bedtime administration
of 5.0 mg terbutaline, but not 2.5 mg,
raised mean plasma glucose concentra-
tionsduringthenight(ANOVAP0.01)
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glucose concentrations were 70 mg/dl
insevenpatients(47%),60mg/dlinsix
(40%), 50 mg/dl in ﬁve (33%), and
40 mg/dl in two (13%) following bed-
time placebo. Corresponding nadir noc-
turnal concentrations were seen in seven,
six, two, and zero patients, respectively,
following administration of 2.5 mg ter-
butaline and in three, zero (P  0.02 vs.
placebo),zero(P0.05vs.placebo),and
zero patients following administration of
5.0 mg terbutaline.
Mean nadir plasma glucose concen-
trations were 87  14 mg/dl following
placebo, 100  14 mg/dl following 2.5
mg terbutaline, and 122  13 mg/dl fol-
lowing 5.0 mg terbutaline (P  0.05 vs.
placebo) (Fig. 1). Mean 0700 h glucose
levels were 113  18, 127  17, and
183  19 mg/dl (P  0.02 vs. placebo),
respectively (Fig. 1). Mean 0700 h heart
rates were 78  5, 82  4, and 88  5
bpm (P  0.02 vs. placebo, respectively).
Terbutaline was seemingly well tolerated.
CONCLUSIONS — These data con-
ﬁrm a high frequency of nocturnal hypo-
glycemia in patients with aggressively
treated type 1 diabetes (1–4). In the ab-
senceofanactivebedtimetreatment(pla-
cebo administration), nadir nocturnal
plasma glucose concentrations were 70
mg/dl(3.9mmol/l),thealertvaluerecom-
mended by the American Diabetes Asso-
ciationWorkgrouponHypoglycemia(8),
in7of15patients(47%).Theywere60
mg/dl (3.3 mmol/l) in six patients (40%),
50 mg/dl (2.8 mmol/l) in ﬁve patients
(33%), and 40 mg/dl (2.2 mmol/l) in
two patients (13%).
These data also conﬁrm that bedtime
administration of 5.0 mg of the epineph-
rine-simulating2-adrenergicagonistter-
butaline effectively prevents nocturnal
hypoglycemia in patients with aggres-
sively treated type 1 diabetes (3) and that
dose of terbutaline increased plasma glu-
cose concentrations throughout the
night, raised the nocturnal nadir plasma
glucose concentration signiﬁcantly, and
eliminatednocturnalplasmaglucosecon-
centrations 60 mg/dl. However, as in
our earlier study (3), it caused hypergly-
cemia the following morning.
Here, we tested the hypothesis that
bedtime administration of 2.5 mg ter-
butaline prevents nocturnal hypoglyce-
mia without causing hyperglycemia the
following morning. That hypothesis was
not conﬁrmed statistically in this small
sample. However, the key efﬁcacy end
points, the number of patients with noc-
turnal plasma glucose concentrations
50 mg/dl and the mean nadir nocturnal
plasmaglucoseconcentration,wereinter-
mediate between those taking placebo at
bedtimeandthosetaking5.0mgterbutal-
ine at bedtime. Documentation of the
efﬁcacy and safety of bedtime administra-
tion of terbutaline in the prevention of
nocturnal hypoglycemia in patients
with type 1 diabetes will require a suit-
ably powered randomized controlled
trial of relatively long-term terbutaline
administration.
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Fig. 1—Mean  SE bedtime (2200 h), nocturnal nadir, and morning (0700 h) plasma glucose
concentrations following bedtime oral administration of placebo, 2.5 mg terbutaline, or 5.0 mg
terbutaline in 15 patients with type 1 diabetes. *P  0.05 vs. placebo. **P  0.02 vs. placebo.
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